{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:01:09Z","timestamp":1788555669206,"version":"build-2803163510"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Convincing epidemiological data have repeatedly shown that increased phosphate levels as well as generous phosphate intakes are associated with unfavourable outcome both in normal and chronically impaired kidney disease (CKD) individuals. Indeed, evidence suggest that impaired phosphate metabolism is associated with markers of cardiovascular damage such as left ventricular hypertrophy, arterial stiffness or vascular calcification as well as mortality. Although current guidelines suggest phosphate control in CKD, evidence on the impact of different approaches to minimize phosphate burden on clinically meaningful outcome are still lacking. How to manipulate, when to start in the course of CKD and to what extent to control phosphate metabolism still remain to be addressed by properly designed clinical studies. Treatment decisions should be based on a risk\u2013benefit assessment to avoid unnecessary exposure to potentially harmful side effects of available compounds. The focus and the ambition of this review are to summarize current evidence and to provide a point of care suggestion on the use of phosphate binders in CKD stage 3 and 4 patients.<\/jats:p>","DOI":"10.1093\/ndt\/gfv405","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T00:16:46Z","timestamp":1450397806000},"page":"184-188","source":"Crossref","is-referenced-by-count":7,"title":["Pro: Should phosphate binders be used in chronic kidney disease stage 3\u20134?"],"prefix":"10.1093","volume":"31","author":[{"given":"Antonio","family":"Bellasi","sequence":"first","affiliation":[{"name":"Sant\u2019 Anna Hospital 1 Division of Nephrology , , Como, CO ,","place":["Italy"]},{"name":"University of Milan 2 Department of Health Sciences , , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,12,17]]},"reference":[{"key":"2025102312481762100_s1-GFV405C1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications","volume":"20","author":"Moranne","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C2","first-page":"20","article-title":"The evolving world of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD)","volume":"1","author":"Bellasi","year":"2013","journal-title":"Eur Med J Nephrol"},{"key":"2025102312481762100_s1-GFV405C3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.5301\/jn.5000258","article-title":"Phosphate binders in moderate chronic kidney disease: where do we stand?","volume":"26","author":"Bellasi","year":"2013","journal-title":"J Nephrol"},{"key":"2025102312481762100_s1-GFV405C4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrneph.2013.111","article-title":"Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism","volume":"9","author":"Kuro-o","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2025102312481762100_s1-GFV405C5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1053\/j.ajkd.2013.02.379","article-title":"Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis","volume":"62","author":"Cozzolino","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2025102312481762100_s1-GFV405C6","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1681\/ASN.2014070642","article-title":"Hyperphosphatemia, phosphoprotein phosphatases, and microparticle release in vascular endothelial cells","volume":"26","author":"Abbasian","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C7","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono","year":"2000","journal-title":"Circ Res"},{"key":"2025102312481762100_s1-GFV405C8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial","volume":"59","author":"Yilmaz","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2025102312481762100_s1-GFV405C9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.atherosclerosis.2007.11.004","article-title":"Phosphorus levels are associated with subclinical atherosclerosis in the general population","volume":"199","author":"Onufrak","year":"2008","journal-title":"Atherosclerosis"},{"key":"2025102312481762100_s1-GFV405C10","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.ajkd.2004.07.022","article-title":"Coronary artery calcification in patients with CRF not undergoing dialysis","volume":"44","author":"Russo","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2025102312481762100_s1-GFV405C11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04100808","article-title":"Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA","volume":"4","author":"Ix","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2215\/CJN.07810910","article-title":"Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction","volume":"6","author":"Bellasi","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/ki.2008.64","article-title":"Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease","volume":"73","author":"Kovesdy","year":"2008","journal-title":"Kidney Int"},{"key":"2025102312481762100_s1-GFV405C14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.02101205","article-title":"Association of disorders in mineral metabolism with progression of chronic kidney disease","volume":"1","author":"Schwarz","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C15","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1681\/ASN.2011020175","article-title":"Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition","volume":"22","author":"Zoccali","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C16","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/ndt\/gfm286","article-title":"High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients","volume":"22","author":"Voormolen","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312481762100_s1-GFV405C17","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.2215\/CJN.01180211","article-title":"Prognosis of CKD patients receiving outpatient nephrology care in Italy","volume":"6","author":"De Nicola","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C18","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C19","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.2215\/CJN.00810110","article-title":"Serum phosphate and mortality in patients with chronic kidney disease","volume":"5","author":"Eddington","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/aje\/kwn285","article-title":"Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality","volume":"169","author":"Onufrak","year":"2009","journal-title":"Am J Epidemiol"},{"key":"2025102312481762100_s1-GFV405C21","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3945\/ajcn.114.085498","article-title":"Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study","volume":"100","author":"Ix","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"2025102312481762100_s1-GFV405C22","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ki.1980.85","article-title":"Renal toxicity of phosphate in rats","volume":"17","author":"Haut","year":"1980","journal-title":"Kidney Int"},{"key":"2025102312481762100_s1-GFV405C23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ndt\/gfs477","article-title":"Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients","volume":"28","author":"Di Iorio","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312481762100_s1-GFV405C24","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"2025102312481762100_s1-GFV405C25","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/ndt\/gfl718","article-title":"Mineral metabolism parameters throughout chronic kidney disease stages 1-5\u2014achievement of K\/DOQI target ranges","volume":"22","author":"Craver","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312481762100_s1-GFV405C26","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage 3\u20134 chronic kidney disease","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney Int"},{"key":"2025102312481762100_s1-GFV405C27","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"2025102312481762100_s1-GFV405C28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ki.2013.3","article-title":"Fibroblast growth factor 23 is not associated with and does not induce arterial calcification","volume":"83","author":"Scialla","year":"2013","journal-title":"Kidney Int"},{"key":"2025102312481762100_s1-GFV405C29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1681\/ASN.2012090894","article-title":"Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes","volume":"24","author":"Dominguez","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C30","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C31","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.2012070719","article-title":"Cardiovascular effects of sevelamer in stage 3 CKD","volume":"24","author":"Chue","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","article-title":"Mortality in kidney disease patients treated with phosphate binders: a randomized study","volume":"7","author":"Di Iorio","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C33","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ki.2011.490","article-title":"Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets","volume":"81","author":"Spiegel","year":"2012","journal-title":"Kidney Int"},{"key":"2025102312481762100_s1-GFV405C34","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1681\/ASN.2011101006","article-title":"Calcium deficiency reduces circulating levels of FGF23","volume":"23","author":"Rodriguez-Ortiz","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481762100_s1-GFV405C35","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"2025102312481762100_s1-GFV405C36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000353569","article-title":"Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease","volume":"38","author":"Seifert","year":"2013","journal-title":"Am J Nephrol"},{"key":"2025102312481762100_s1-GFV405C37","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","article-title":"Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial","volume":"62","author":"Di Iorio","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2025102312481762100_s1-GFV405C38","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int"},{"key":"2025102312481762100_s1-GFV405C39","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"key":"2025102312481762100_s1-GFV405C40","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/31\/2\/184\/7430089\/gfv405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/31\/2\/184\/7430089\/gfv405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:48:47Z","timestamp":1761238127000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/31\/2\/184\/2460111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,17]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,12,17]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfv405","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726022266.793515575","asserted-by":"object"}]},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,2]]},"published":{"date-parts":[[2015,12,17]]}}}